Bullfrog AI Holdings, Inc. (BFRG) - Not Halal (Non-Compliant)
Bullfrog AI Holdings, Inc. (BFRG) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
- Sector
- Healthcare
- Industry
- Health Information Services
- Result
- Pass
- Reason
- The sector "Healthcare" and industry "Health Information Services" are not in the excluded categories.
Financial Ratios
- Debt Ratio
- Value: 0.6% | Threshold: 30% | Result: Pass
- Cash & Interest-bearing Securities Ratio
- Value: 43.0% | Threshold: 30% | Result: Fail
- Non-Permissible Income Ratio
- Value: 47.9% | Threshold: 5% | Result: Fail
Dividend Purification
Purification percentage: 47.93%.Based on the company's financial statements, approximately 47.93% of dividend income should be donated to charity for purification. This is derived from identified interest income (47.93% of total income). Some scholars may differ on the exact calculation method.
About Bullfrog AI Holdings, Inc.
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.